Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

MedPage Today
medpagetoday.com > infectiousdisease > generalinfectiousdisease > 122944

Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

3+ day, 21+ hour ago   (135+ words) The danger may be in the dosing, not in the drug itself...

Google News
medpagetoday.com > meetingcoverage > ers > 122943

IL-33 Inhibitor Delivers in COPD Trials

4+ day, 15+ hour ago   (661+ words) — Tozorakimab highly promising as biologic therapy in replicate phase III trials A broad population of people with chronic obstructive pulmonary disease (COPD), current and former smokers alike, experienced fewer exacerbations taking a first-in-class biologic targeting interleukin (IL)-33, a pair of…...

Google News
medpagetoday.com > gastroenterology > coloncancer > 122942

H. Pylori Exposure and Colorectal Cancer: The Evidence Grows

4+ day, 15+ hour ago   (614+ words) — Modeling study suggests an association Exposure to Helicobacter pylori, known for its role in gastric cancer, may also play a role in colorectal cancer (CRC), according to results from a risk-attribution modeling study. Based on estimates from 43 studies, H. pylori…...

MedPage Today
medpagetoday.com > hematologyoncology > prostatecancer > 122905

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

1+ week, 3+ day ago   (229+ words) — News, features, and commentary about cancer-related issues The FDA approved ropeginterferon alfa-2b (Besremi) injection to treat adults with essential thrombocythemia, the first new therapy for the chronic blood cancer since the 1997 approval of anagrelide. A national survey showed that almost…...

MedPage Today
medpagetoday.com > infectiousdisease > longcovid > 122886

Is Paxlovid Any Better Than Placebo for Long COVID?

1+ week, 3+ day ago   (181+ words) In three major symptom phenotypes, randomized trial finds no benefit...

MedPage Today
medpagetoday.com > dermatology > generaldermatology > 122879

Dramatic Improvement in Dermatomyositis Skin Symptoms With First Approved Oral Agent

1+ week, 3+ day ago   (29+ words) Lesion clearance rate, itch reduction doubled with TYK2/JAK1 inhibitor brepocitinib...

MedPage Today
medpagetoday.com > cardiology > generalcardiology > 122860

Sad Trial Names: Social Media Thinks Cardiology Is Going Through It

1+ week, 4+ day ago   (376+ words) — Two trials from the same research group sound like vulnerable relationship status updates Cardiology is going through it -- so say commenters on social media, at least. During last week's European Society of Cardiology (ESC) meeting in Munich, a trial name…...

MedPage Today
medpagetoday.com > nephrology > anemia > 122845

FDA Adds Boxed Warning to Iron Replacement Injection

1+ week, 5+ day ago   (167+ words) — Label change for ferric carboxymaltose warns of risk for symptomatic hypophosphatemia The FDA approved a label change for ferric carboxymaltose injection (Injectafer) that adds a boxed warning for the risk of symptomatic hypophosphatemia. The agency recommends monitoring of phosphate levels…...

MedPage Today
medpagetoday.com > pediatrics > obesity > 122837

GLP-1 Drugs Tied to Gallbladder and Biliary Risks in Youth

1+ week, 6+ day ago   (427+ words) — Real-world study identifies safety signal in young people with overweight or obesity Use of GLP-1 receptor agonists was associated with increased cumulative gallbladder and biliary events in youths, according to a retrospective analysis of TriNetX data. Among over 37,000 adolescents and…...

MedPage Today
medpagetoday.com > hematologyoncology > hematology > 122831

First-in-Class Drug Wins FDA Approval for Polycythemia Vera

1+ week, 6+ day ago   (320+ words) — Rusfertide mimics hepcidin to target erythrocytosis in rare blood malignancy The FDA approved first-in-class rusfertide (Mimrylo)opens in a new tab or window for treating erythrocytosis in adults with polycythemia vera (PV), a rare and slow-growing hematologic malignancy. Rusfertide mimics…...